Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
4 search results for:

290 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 04-06-2022 | ASCO 2022 | Conference coverage | Article

    Adjuvant everolimus may benefit RCC patients at high risk for recurrence

    In total, 290 patients died during follow-up; the estimated 5-year overall survival (OS) rate was 87% with everolimus and 85% with placebo.

    Author:
    Laura Cowen
    Published in:
    2022 ASCO Annual Meeting; Chicago, Illinois, USA: 3–7 June
  2. 12-08-2020 | Non-small-cell lung cancer | News | Article
    WCLC Virtual Presidential Symposium 2020

    Ensartinib ‘a new first-line option’ for ALK-positive NSCLC

    She reported on a preplanned interim analysis of the intention-to-treat (ITT) population that included 290 participants with locally confirmed ALK -positive, stage IIIB or IV disease who had not previously received an ALK inhibitor and had received no more than one prior chemotherapy regimen.

    Author:
    Shreeya Nanda
    Published in:
    WCLC Virtual Presidential Symposium 2020: 8 August
  3. 26-07-2017 | Teaser

    The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

    Therapies that treat cancer by modulating the immune response have led to unprecedented results in patients with advanced-stage tumors. This review discusses the latest advances in immunotherapy and its role in the future of cancer treatment. Summary points Cancer immunotherapies have the potential to generate robust antitumor responses; this can be achieved through several methods, such as modulatory antibodies or adoptive cellular therapy. Since 2010, clinical trials using different immunotherapeutic approaches to treat patients with several tumor types have yielded unprecedented results. In contrast with therapies that act on the tumor itself, immunotherapy-dependent antitumor responses can be sustained after the treatment has finished. The optimal efficacy of immunotherapy will likely be achieved with designs that include combinations of different immunotherapeutic approaches, or immunotherapy combined with other cancer treatments. Khalil​​​​​​​ DN et al.  Nat Rev Clin Oncol 2016; 13: 273–290. doi:10.1038/nrclinonc.2016.25

  4. 15-03-2016 | Treatment | Article

    The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

    Therapies that treat cancer by modulating the immune response have led to unprecedented results in patients with advanced-stage tumors. This review discusses the latest advances in immunotherapy and its role in the future of cancer treatment. Nat Rev Clin Oncol 2016; 13: 273–290. doi:10.1038/nrclinonc.2016.25

    Author:
    Danny N. Khalil, Eric L. Smith, Renier J. Brentjens, Jedd D. Wolchok
  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.